{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:43:06Z","timestamp":1779212586261,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jval.2023.09.001","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T03:19:52Z","timestamp":1695266392000},"page":"1689-1696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis"],"prefix":"10.1016","volume":"26","author":[{"given":"Xue","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Sun","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Lachaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Pratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akanksha","family":"Dua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cat N.","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jval.2023.09.001_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jval.2023.09.001_bib2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jval.2023.09.001_bib3","first-page":"38","article-title":"Acute myeloid leukemia: a review","volume":"103","author":"Pelcovits","year":"2020","journal-title":"RI Med J"},{"key":"10.1016\/j.jval.2023.09.001_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106339","article-title":"Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia","volume":"91","author":"Griffiths","year":"2020","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.jval.2023.09.001_bib6","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.2009.25.1066","article-title":"Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study","volume":"28","author":"Walter","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.jval.2023.09.001_bib7","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1056\/NEJMe1611424","article-title":"Acute myeloid leukemia - many diseases, many treatments","volume":"375","author":"Estey","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jval.2023.09.001_bib8","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jval.2023.09.001_bib9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jval.2023.09.001_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/joim.13293","article-title":"Acute myeloid leukaemia in patients we judge as being older and\/or unfit","volume":"290","author":"Lazarevic","year":"2021","journal-title":"J\u00a0Intern Med"},{"issue":"2","key":"10.1016\/j.jval.2023.09.001_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11899-010-0048-8","article-title":"Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia","volume":"5","author":"Ritchie","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jval.2023.09.001_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720913010","article-title":"Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia","volume":"11","author":"Vey","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"10.1016\/j.jval.2023.09.001_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jval.2023.09.001_bib15","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.jval.2023.09.001_bib16","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A\u00a0comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jval.2023.09.001_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/10428194.2021.1973669","article-title":"Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy","volume":"63","author":"Li","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jval.2023.09.001_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jval.2023.09.001_bib24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jval.2023.09.001_bib25","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jval.2023.09.001_bib26","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.jval.2023.09.001_bib28","series-title":"TIBSOVO [Package insert]","year":"2021"},{"key":"10.1016\/j.jval.2023.09.001_bib29","author":"Dias"},{"key":"10.1016\/j.jval.2023.09.001_bib30","author":"Dias"},{"issue":"4","key":"10.1016\/j.jval.2023.09.001_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"Gelman","year":"1992","journal-title":"Statist Sci"},{"issue":"2","key":"10.1016\/j.jval.2023.09.001_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jval.2023.09.001_bib33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.jval.2023.09.001_bib34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.jval.2023.09.001_bib35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jval.2023.09.001_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.09.001_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2011.606382","article-title":"Azacitidine in patients with acute\u00a0myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I\/II study","volume":"53","author":"Al-Ali","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2023.09.001_bib38","doi-asserted-by":"crossref","unstructured":"Oh S, Kim E. Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis [published online March 25, 2023]. Clin Exp Med. doi:10.1007\/s10238-023-01041-0","DOI":"10.1007\/s10238-023-01041-0"},{"key":"10.1016\/j.jval.2023.09.001_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.leukres.2018.02.002","article-title":"Interpretation of clinical endpoints in trials of acute myeloid leukemia","volume":"68","author":"Medeiros","year":"2018","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.jval.2023.09.001_bib40","first-page":"1562","article-title":"Response rates as predictors of overall survival: a meta-analysis of acute myeloid leukemia trials","volume":"8","author":"Agarwal","year":"2017","journal-title":"J\u00a0Cancer"},{"issue":"5","key":"10.1016\/j.jval.2023.09.001_bib41","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2006-08-041152","article-title":"End points to establish the efficacy of new agents in the treatment of acute leukemia","volume":"109","author":"Appelbaum","year":"2007","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jval.2023.09.001_bib42","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.jval.2023.09.001_bib43","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.jval.2023.09.001_bib44","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1182\/blood.V128.22.1613.1613","article-title":"Complete remissions (CRs) with azacitidine regimens compared to Crs with 7+ 3 induction chemotherapy and the effect on overall survival","volume":"128","author":"Othus","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jval.2023.09.001_bib45","first-page":"73","article-title":"Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?","volume":"38","author":"Vey","year":"2013","journal-title":"Interdiscip Top Gerontol"},{"issue":"5","key":"10.1016\/j.jval.2023.09.001_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11864-021-00841-4","article-title":"New treatment options for older patients with acute myeloid leukemia","volume":"22","author":"Saxena","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"10.1016\/j.jval.2023.09.001_bib47","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.jval.2023.09.001_bib48","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jval.2023.09.001_bib49","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1471-2288-12-138","article-title":"Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons","volume":"12","author":"Song","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"10.1016\/j.jval.2023.09.001_bib50","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jval.2019.05.013","article-title":"A\u00a0comparison of national guidelines for network meta-analysis","volume":"22","author":"Laws","year":"2019","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2023.09.001_bib51","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jval.2014.06.001","article-title":"A\u00a0comparison of national guidelines for network meta-analysis","volume":"17","author":"Laws","year":"2014","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2023.09.001_bib54","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jrsm.1195","article-title":"GetReal in network meta-analysis: a review of the methodology","volume":"7","author":"Efthimiou","year":"2016","journal-title":"Res Synth Methods"},{"issue":"2","key":"10.1016\/j.jval.2023.09.001_bib55","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"suppl 15","key":"10.1016\/j.jval.2023.09.001_bib56","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1200\/JCO.2020.38.15_suppl.7509","article-title":"Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up","volume":"38","author":"Heuser","year":"2020","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523031248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523031248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:33:06Z","timestamp":1761096786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301523031248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1098301523031248"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.09.001","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}